Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Prescient Therapeutics Limited ( (AU:PTX) ) is now available.
Prescient Therapeutics Limited has issued 21.78 million unquoted options under its employee incentive scheme, exercisable at A$0.10 and expiring on 17 November 2029. The move is designed to align staff incentives with long-term shareholder value and supports the company’s efforts to retain and motivate key employees as it advances its oncology drug development pipeline.
More about Prescient Therapeutics Limited
Prescient Therapeutics Limited is an ASX-listed biotechnology company focused on developing cancer therapies. The company operates in the biopharmaceutical sector, leveraging targeted and personalised medicine approaches to address unmet needs in oncology markets.
Average Trading Volume: 1,839,131
Technical Sentiment Signal: Buy
Current Market Cap: A$110.4M
See more data about PTX stock on TipRanks’ Stock Analysis page.